SECURITIES AND EXCHANGE COMMISSION

17 CFR Parts 239 and 274


RIN 3235–AJ44

Enhanced Disclosure and New Prospectus Delivery Option for Registered Open-End Management Investment Companies

AGENCY: Securities and Exchange Commission.

ACTION: Final rule; correction.

SUMMARY: In connection with rules adopted in Release No. 33–8998 (January 13, 2009), which appeared in the Federal Register on January 26, 2009 (74 FR 4546), the Securities and Exchange Commission is making technical corrections to Form N–1A and Form N–4. Specifically, the Commission is correcting certain cross-references appearing in each Form and correcting a citation appearing in Form N–1A. The citation being corrected was originally adopted in its incorrect form in Release No. IC–23064 (Mar. 13, 1998), which appeared in the Federal Register on March 23, 1998 (63 FR 13916).

DATES: Effective Date: June 4, 2009.

FOR FURTHER INFORMATION CONTACT:
Kieran G. Brown, Senior Counsel, Office of Disclosure Regulation, at (202) 551–6784; Division of Investment Management, Securities and Exchange Commission, 100 F Street, NE., Washington, DC 20549–5720.

SUPPLEMENTARY INFORMATION: The Commission is making the following corrections to Release No. 33–8998 (January 13, 2009), which was published in FR Doc E9–1035 appearing on page 4546 in the Federal Register on January 26, 2009:

Note: The text of the form does not, and these amendments will not, appear in the Code of Federal Regulations.

1. On page 4588, second column, amendment 13, paragraph m.ii., beginning on line four, revise the reference “Items 17(d) and 22(b)” to read “Items 17(d) and 23(b)”.

2. On page 4588, second column, amendment 13, paragraph m.iii., on the second line, revise “reference” to read “references”, and on the third line, revise the reference “Item 22(a)” to read “Item 23(a)”.

3. On page 4593, second column, add amendment 13(a) to read as follows:

13(a). Form N–1A (referenced in §§ 239.15A and 274.11A) is amended by:

a. In the General Instructions, revising the citation “[15 U.S.C. 80a–24(f)]” in paragraph B.3. to read “[15 U.S.C. 80a–24(f)]”; and

b. In newly redesignated Item 17(c)(2), revising the reference “paragraph (d)(1)” to read “paragraph (c)(1)”.

4. On page 4593, second column, amendment 14, beginning on the fourth line and continuing on to the third column, revise the reference “Item 27(b)(ii) of Form N–1A” to read “Item 20(b)(c)”.

5. In paragraph B.3. to read “paragraph (c)(i)”.

This rule does not meet the definition of “rule” in 5 U.S.C. 804(3)(A) because it is a rule of “particular applicability.” Therefore, it is not subject to the congressional review requirements in 5 U.S.C. 801–808.

List of Subjects in 21 CFR Part 524

Animal drugs.

Therefore, under the Federal Food, Drug, and Cosmetic Act and under authority delegated to the Commissioner of Food and Drugs and delegated to the Center for Veterinary Medicine, 21 CFR part 524 is amended as follows:

PART 524—OPHTHALMIC AND TOPICAL DOSAGE FORM NEW ANIMAL DRUGS

1. The authority citation for 21 CFR part 524 continues to read as follows: Authority: 21 U.S.C. 360b.

§ 524.590 [Amended]

2. In paragraph (b) of § 524.590, remove “065274” and in its place add “000010”.

§ 524.1195 [Amended]

3. In paragraph (b) of § 524.1195, remove “065274” and in its place add “000010”.

Dated: May 27, 2009.

Bernadette Dunham,
Director, Center for Veterinary Medicine.

[FR Doc. E9–13015 Filed 6–3–09; 8:45 am]

BILLING CODE 4160–01–S

DEPARTMENT OF HEALTH AND HUMAN SERVICES

Food and Drug Administration

21 CFR Part 524

[Docket No. FDA–2009–N–0665]

Opthalmic and Topical Dosage Form New Animal Drugs; Change of Sponsor; Diclofenac; Ivermectin Otic Suspension

AGENCY: Food and Drug Administration, HHS.

ACTION: Final rule.

SUMMARY: The Food and Drug Administration (FDA) is amending the animal drug regulations to reflect a change of sponsor for diclofenac sodium cream and ivermectin otic suspension from IDEXX Pharmaceuticals, Inc., to Boehringer Ingelheim Vetmedica, Inc.

DATES: This rule is effective June 4, 2009.

FOR FURTHER INFORMATION CONTACT:
David R. Newkirk, Center for Veterinary Medicine, 2100 L St., N.W., Washington, DC 20201.

SUPPLEMENTARY INFORMATION: IDEXX Pharmaceuticals, Inc., 7009 Albert Pick Rd., Greensboro, NC 27409, has informed FDA that it has transferred ownership of, and all rights and interest in, NADA 141–186 for SURPASS (diclofenac sodium) topical cream and NADA 141–174 for ACAREXX (ivermectin) otic suspension to Boehringer Ingelheim Vetmedica, Inc., 2621 North Belt Highway, St. Joseph, MO 64506–2002. Accordingly, the regulations are amended in 21 CFR 524.590 and 524.1195 to reflect the change of sponsorship.

This rule does not meet the definition of “rule” in 5 U.S.C. 804(3)(A) because it is a rule of “particular applicability.” Therefore, it is not subject to the congressional review requirements in 5 U.S.C. 801–808.

List of Subjects in 21 CFR Part 524

Animal drugs.

Therefore, under the Federal Food, Drug, and Cosmetic Act and under authority delegated to the Commissioner of Food and Drugs and delegated to the Center for Veterinary Medicine, 21 CFR part 524 is amended as follows:

PART 524—OPHTHALMIC AND TOPICAL DOSAGE FORM NEW ANIMAL DRUGS

1. The authority citation for 21 CFR part 524 continues to read as follows: Authority: 21 U.S.C. 360b.

§ 524.590 [Amended]

2. In paragraph (b) of § 524.590, remove “065274” and in its place add “000010”.

§ 524.1195 [Amended]

3. In paragraph (b) of § 524.1195, remove “065274” and in its place add “000010”.

Dated: May 27, 2009.

Bernadette Dunham,
Director, Center for Veterinary Medicine.

[FR Doc. E9–13015 Filed 6–3–09; 8:45 am]

BILLING CODE 4160–01–S

DEPARTMENT OF HOMELAND SECURITY

Coast Guard

33 CFR Part 165

[Docket No. USCG–2009–0267]

RIN 1625–AA00

Safety Zone; Sea World June Fireworks; Mission Bay, San Diego, CA

AGENCY: Coast Guard, DHS.

ACTION: Temporary final rule.

SUMMARY: The Coast Guard establishes a safety zone, on the navigable waters of Mission Bay in